Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Progressive Metastatic Castrate-Resistant Prostate Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Not applicableStudy completedNCT02025413
What this trial is testing

Isolation of Circulating Tumor Cells Using a Novel EMT-Based Capture Method

Who this might be right for
Metastatic Progressive Castration-resistant Prostate CancerMetastatic Progressive Breast Cancer
Duke University 46
Large-scale testing (Phase 3)Ended earlyNCT04876651
What this trial is testing

The Present Study Aims to Compare Patients Who Receive the Investigational Product (177Lu-DOTA-rosopatamab) Plus Standard of Care, in Comparison to Standard of Care Only

Who this might be right for
Metastatic Prostate Cancer
Telix Pharmaceuticals (Innovations) Pty Ltd 16
Early research (Phase 1)Ended earlyNCT03490838
What this trial is testing

177Lu-PSMA-R2 in Patients With PSMA Positive Progressive, Metastatic, Castration Resistant Prostate Cancer

Who this might be right for
Prostatic Neoplasm
Advanced Accelerator Applications 27
Large-scale testing (Phase 3)Ended earlyNCT00676650
What this trial is testing

Sunitinib Plus Prednisone In Patients With Metastatic Castration-Resistant Prostate Cancer After Failure Of Docetaxel Chemotherapy

Who this might be right for
Prostatic Neoplasms
Pfizer 873
Testing effectiveness (Phase 2)Active Not RecruitingNCT01688492
What this trial is testing

Combining Ipilimumab With Abiraterone Acetate Plus Prednisone in Chemotherapy and Immunotherapy-naïve Patients With Progressive Metastatic Castration-resistant Prostate Cancer

Who this might be right for
Prostate Cancer
Memorial Sloan Kettering Cancer Center 54
Testing effectiveness (Phase 2)Looking for participantsNCT04946370
What this trial is testing

Phase I/II Trial of Pembrolizumab and Androgen-receptor Inhibitor With or Without 225Ac-J591 for Progressive Metastatic Castration Resistant Prostate Cancer

Who this might be right for
Prostate Cancer
Weill Medical College of Cornell University 52
Testing effectiveness (Phase 2)Active Not RecruitingNCT05658003
What this trial is testing

A Study Evaluating [177Lu]Lu-PSMA-617 vs. a Change of Androgen Receptor-directed Therapy in Taxane Treatment Naive Chinese Male Patients With Progressive Metastatic Castrate Resistant Prostate Cancer

Who this might be right for
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Novartis Pharmaceuticals 63
Large-scale testing (Phase 3)Active Not RecruitingNCT04689828
What this trial is testing

177Lu-PSMA-617 vs. Androgen Receptor-Directed Therapy in the Treatment of Progressive Metastatic Castrate Resistant Prostate Cancer

Who this might be right for
Prostatic Neoplasms
Novartis Pharmaceuticals 469
Testing effectiveness (Phase 2)Ended earlyNCT00479635
What this trial is testing

A Phase II Trial of TPI 287 in Patients With Metastatic Prostate Cancer

Who this might be right for
Prostate Cancer
Cortice Biosciences, Inc. 26
Testing effectiveness (Phase 2)Study completedNCT01091103
What this trial is testing

Determine Effect of Enzalutamide (MDV3100) on the Androgen Signaling Pathway in Correlation With the Anti-tumor Effects of Enzalutamide

Who this might be right for
Metastatic Progressive Castration-resistant Prostate Cancer
Pfizer 60
Testing effectiveness (Phase 2)Active Not RecruitingNCT03725761
What this trial is testing

Sacituzumab Govitecan in Patients With Metastatic Castration-Resistant Prostate Cancer Progressing on Second Generation AR-Directed Therapy

Who this might be right for
Prostate Cancer
University of Wisconsin, Madison 31
Testing effectiveness (Phase 2)Active Not RecruitingNCT06004661
What this trial is testing

Study of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moderately and Severely Impaired and With Normal Renal Function

Who this might be right for
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Novartis Pharmaceuticals 23
Not applicableStudy completedNCT04281147
What this trial is testing

Study to Gather Information About the Use of Healthcare Services and the Way the Disease is Cared for in Canadian Patients With Prostate Gland Cancer Which Spread Throughout the Body

Who this might be right for
Prostate Cancer
Bayer 4,301
Testing effectiveness (Phase 2)Active Not RecruitingNCT06894511
What this trial is testing

An Open-label Study of Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI Versus AAA617 in PSMA Positive First-line mCRPC

Who this might be right for
Metastatic Castration Resistant Prostate Cancer (mCRPC)
Novartis Pharmaceuticals 7
Early research (Phase 1)Study completedNCT01692262
What this trial is testing

Investigating Safety, Tolerability and Efficacy of AZD5363 in Prostate Cancer.

Who this might be right for
Metastatic Castrate-Resistant Prostate Cancer (mCRPC),Efficacy,Safety and Tolerability,+3 more
AstraZeneca 59
Testing effectiveness (Phase 2)Study completedNCT02814968
What this trial is testing

PET/CT and WB MRI for Staging and Response in CRPC Patients Receiving Enzalutamide

Who this might be right for
Prostate Cancer Metastatic
The European Uro-Oncology Group 66
Testing effectiveness (Phase 2)Ended earlyNCT03531827
What this trial is testing

Combining CRLX101, a Nanoparticle Camptothecin, With Enzalutamide in People With Progressive Metastatic Castration Resistant Prostate Cancer Following Prior Enzalutamide Treatment

Who this might be right for
Metastatic Castration Resistant Prostate CancerProstate Neoplasms
National Cancer Institute (NCI) 4
Testing effectiveness (Phase 2)Study completedNCT01171898
What this trial is testing

Safety, Pharmacokinetic and Proof-of-Concept Study of ARN-509 (Apalutamide) in Castration-Resistant Prostate Cancer (CRPC)

Who this might be right for
Prostate Cancer
Aragon Pharmaceuticals, Inc. 127
Testing effectiveness (Phase 2)Study completedNCT02445976
What this trial is testing

Once-daily Oral Seviteronel in Patients With Castration-Resistant Prostate Cancer Progressing on Enzalutamide or Abiraterone.

Who this might be right for
Prostate Cancer
Innocrin Pharmaceutical 197
Testing effectiveness (Phase 2)Ended earlyNCT03869762
What this trial is testing

Denosumab in Combination With Enzalutamide in Progressive Metastatic Castrate-resistant Prostate Cancer and Bone Metastases.

Who this might be right for
Castration-resistant Prostate CancerMetastatic CancerBone Metastases
Cancer Trials Ireland 7
Next Page